Evidence map›Paper›PMID 33239866›Full record

ArticleDrug design, development and therapy2020

Acacetin Induces Apoptosis in Human Osteosarcoma Cells by Modulation of ROS/JNK Activation.

Shubin Wang, Binhui Lin, Wei Liu, Guojun Wei, Zongguang Li, Naichun Yu, Xiang Xue, Guangrong Ji

Open access · goldAbstract read
In one paragraph

Article in Drug design, development and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Artesunate induces ferroptosis in osteosarcoma through NCOA4-mediated ferritinophagy.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  8. Review
  9. Anticancer Potential of Bioactive Compounds inCancer management and research · 2025
    Review
  10. Review
  11. Effect of acacetin on inhibition of apoptosis inWorld journal of gastrointestinal oncology · 2024
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. MLN2238 exerts its anti-tumor effectsFrontiers in pharmacology · 2022
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Shubin WangDepartment of Orthopedic Surgery, Xiang'an Hospital of Xiamen University, Xiamen City, Fujian, People's Republic of China.
Binhui LinDepartment of Orthopedic Surgery, Xiang'an Hospital of Xiamen University, Xiamen City, Fujian, People's Republic of China.
Wei LiuDepartment of Orthopedic Surgery, Xiang'an Hospital of Xiamen University, Xiamen City, Fujian, People's Republic of China.
Guojun WeiDepartment of Orthopedic Surgery, Xiang'an Hospital of Xiamen University, Xiamen City, Fujian, People's Republic of China.
Zongguang LiDepartment of Orthopedic Surgery, Xiang'an Hospital of Xiamen University, Xiamen City, Fujian, People's Republic of China.
Naichun YuDepartment of Orthopedic Surgery, Xiang'an Hospital of Xiamen University, Xiamen City, Fujian, People's Republic of China.
Xiang XueDepartment of Orthopedic Surgery, Xiang'an Hospital of Xiamen University, Xiamen City, Fujian, People's Republic of China.
Guangrong JiDepartment of Orthopedic Surgery, Xiang'an Hospital of Xiamen University, Xiamen City, Fujian, People's Republic of China.
Xiamen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe long-term survival rate of osteosarcoma, which is the most common type of primary malignant bone tumor, has stagnated in past decades. Acacetin is a natural flavonoid compound that has antioxidative and anti-inflammatory effects and exhibits extensive therapeutic effects on various cancers. In this study, the anticancer potential of acacetin and the underlying molecular mechanisms were examined in human osteosarcoma cells (SJSA and HOS). MATERIALS AND

methodsHOS and SJSA cell lines were exposed to different concentrations of acacetin. Cell proliferation and viability were assessed by CCK-8 and colony-formation assays. Hoechst 33258 fluorescent staining was employed to detect apoptosis. Cell apoptosis was measured by an annexin V-FITC/PI assay by flow cytometry. The alteration in the mitochondrial membrane potential was detected by a JC-1 Assay Kit. Apoptosis-related protein expression was determined by Western blotting. Intracellular reactive oxygen species (ROS) production was detected by fluorescence microscopy and flow cytometry. Subsequently, the activation of the ROS/JNK signaling pathway was investigated.

resultsAcacetin could inhibit proliferation and induce apoptosis in SJSA and HOS cells. The acacetin treatment resulted in the activation of caspase-3, -8, and -9 and cleaved PARP. Further studies showed that acacetin-induced apoptosis was attributed to ROS. In addition, we found that acacetin induced the activation of the downstream c-Jun N-terminal kinase (JNK) signaling pathway. Subsequently, after treatment with the ROS scavenger GSH and the JNK inhibitor SP600125, the apoptosis-inducing effect triggered by acacetin was significantly attenuated.

conclusionThe results of the present study indicate that acacetin may induce apoptosis to inhibit cell growth by activating the ROS/JNK signaling pathway in SJSA and HOS cells, suggesting that acacetin may be a promising candidate for the management of osteosarcomas.

Indexed as

AnthracenesAntineoplastic AgentsApoptosisBone NeoplasmsCell ProliferationCells, CulturedCell SurvivalDose-Response Relationship, DrugDrug Screening Assays, AntitumorFlavonesHumansJNK Mitogen-Activated Protein KinasesOsteosarcomaReactive Oxygen SpeciesacacetinAnthracenesAntineoplastic AgentsFlavonesJNK Mitogen-Activated Protein KinasespyrazolanthroneReactive Oxygen SpeciesacacetinapoptosisosteosarcomaROS/JNK activation

Identifiers

PMID33239866
PMCPMC7680676
OpenAlexW3099766205

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.